Today’s biopharma news highlights how new data could reduce treatment burden, improve excipient information sharing, and shape future options for patients with difficult-to-treat cancers.
|Articles|March 12, 2008
Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America
Author(s)BioPharm International Editors
Sanofi Pasteur (Lyon, France) has shipped six million doses of its Stamaril yellow fever vaccine in response to the to the yellow fever epidemic in Latin America.
Advertisement
Sanofi Pasteur (Lyon, France) has shipped six million doses of its Stamaril yellow fever vaccine in response to the to the yellow fever epidemic in Latin America.
Brazil received four million doses and Paraguay received two million doses of the Stamaril vaccine in response to urgent requests from health authorities.
The yellow fever vaccine that was provided to Brazil and Paraguay is part of the UNICEF vaccine stockpile, which is reserved for outbreak responses. Sanofi Pasteur is currently the only vaccine supplier to the vaccine stockpile.
Advertisement
Related to this article
Daiichi Sankyo and Merck pulled ifinatamab deruxtecan's FDA filing in small cell lung cancer after a 187-patient trial fell short.
IPEC’s EIP user guide streamlines information exchange and response times while increasing accuracy through standardization.
Insulin efsitora alfa-gobe (Onswik) cuts injections from 365 to 52 a year for adults with type 2 diabetes, per its new FDA approval.
Genentech is paying Earendil Labs $55 million upfront in a deal worth over $1.5 billion to develop bispecific antibodies for hard-to-treat cancers.
Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.
Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.
AstraZeneca's sBLA for durvalumab combined with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer, based on the Phase 3 VOLGA trial, has a PDUFA date expected in the fourth quarter of 2026.
Advertisement
Advertisement